Does My Insurance Cover Keytruda?
Keytruda (pembrolizumab) coverage depends on your specific insurance plan, the reason for treatment, and prior authorization requirements. Most Medicare Part B plans cover it for FDA-approved uses like certain cancers (e.g., melanoma, lung cancer), often with 80% payment after the deductible. Private insurers like Blue Cross Blue Shield or UnitedHealthcare typically cover it too, but only if deemed medically necessary by your doctor.[1] Check your plan's formulary or call your insurer to confirm.
How to Check Coverage for Keytruda on Your Plan
Log into your insurance portal or use their app to search "Keytruda" in the drug lookup tool. Provide details like dosage (usually 200mg IV every 3 weeks) and diagnosis code. If it's specialty pharmacy-required, your oncologist's office can submit a prior authorization form. Tools like GoodRx or the Keytruda Copay Program site help estimate costs.[2]
What If Insurance Denies Keytruda Coverage?
Denials often stem from off-label use, step therapy (trying cheaper drugs first), or insufficient documentation. Appeal with your doctor's letter of medical necessity, clinical trial data, or NCCN guidelines supporting Keytruda. Patient assistance from Merck (Keytruda's maker) covers copays up to $25,000/year for eligible commercially insured patients.[3]
Keytruda Costs Without Insurance
A single infusion runs $10,000–$12,000, with a full course (e.g., 2 years) exceeding $150,000. Medicare patients pay 20% coinsurance post-deductible (~$2,000–$2,400 per cycle). Uninsured options include Merck's patient support program for free or discounted doses based on income.[4]
Medicare vs. Private Insurance Coverage Differences
| Aspect | Medicare Part B | Private Insurance |
|--------|-----------------|-------------------|
| Coverage Trigger | FDA-approved indications; hospital outpatient | Prior auth + medical necessity; often excludes experimental use |
| Copay | 20% after $240 deductible (2024) | $0–$5,000/dose; varies by tier (specialty drug) |
| Appeals Success | High for oncology (~70%) | Lower if not on formulary |
| Caps | No out-of-pocket max for Part B drugs | Often $2,000–$10,000 annual max |
Medicare covers more reliably for approved cancers but lacks a cap; private plans cap costs but scrutinize more.[5]
Keytruda Patient Assistance and Copay Programs
Merck's program reduces copays to $0 for eligible patients (income <500% FPL). NeedyMeds or RxAssist list additional nonprofits. Biosimilars aren't available yet—patents expire around 2028 in the US.[6]
[1]: CMS.gov - Medicare Coverage of Immunotherapy
[2]: Keytruda.com - Coverage & Savings
[3]: Merck Patient Assistance
[4]: GoodRx - Keytruda Pricing
[5]: KFF.org - Cancer Drug Coverage
[6]: DrugPatentWatch.com - Keytruda Patents